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RecentstudieshaveshownanincreasedriskofarterialandvenousvasculardiseasesinHIVpatients,pulmonarythromboembolism
being one of them. HIV-infected individuals may have procoagulants predisposing them to thromboembolism. Patients with
thromboembolism may have a clinical presentation mimicking common opportunistic infections. It is important to consider
pulmonary embolism in the diﬀerential of HIV patients with fever, cough, and dyspnea, particularly in those with well-controlled
HIV infection.
1.Introduction
Infection with the human immunodeﬁciency virus (HIV)
is now a chronic disease in the developed world. HIV-
infected patients have a better life expectancy with the
advent of highly potent antiretroviral therapy (ARV) than
in the past. However, chronic HIV infection and ARVs
are now associated with long-term complications [1]. In
recent literature, the relationship between HIV infection
and cardiovascular disease has been addressed. Studies have
shown an increased risk of arterial and venous vascular
diseases in HIV patients. For example, a cohort study
comparing 4993 HIV patients revealed an incidence of
myocardial infarction of 0.59 to 3.41/1000 patient-years
[2], another with 23,468 HIV-positive patients found an
incidence of myocardial infarction of 3.5/1000 patient-years
[3]. In a systematic review of literature from 1986 to 2004,
Klein et al. reported that the incidence of venous thrombotic
events in HIV-infected patients was increased two to ten-fold
in comparison with healthy individuals of similar age [1].
In a series of HIV-positive patients with venous or arterial
thrombosis, pulmonary emboli accounted for 66% of all
thrombotic events [4].
2. Case Presentation
A 41-year-old man with a history of HIV (diagnosed
in 1988) on ARVs presented with three days of non-
productive cough, intermittent fever, chills, dyspnea on
exertion, and generalized fatigue. His past medical history
included Cytomegalovirus retinitis with bilateral blindness,
Kaposi’s sarcoma, lipodystrophy and lipoatrophy, hypothy-
roidism, and hypertension. His medications included aba-
cavir/lamivudine, ritonavir, atazanavir, pravastatin, met-
formin, levothyroxine, and valsartan. The patient’s last
CD4 cell count was 800cells/mm3, and the viral load was
undetectable ﬁve months previously while on his current
antiretroviral regimen.
The patient was febrile at 100.8◦F, pulse of 118/min,
blood pressure 93/65mm of Hg, respiratory rate 18/min,
and oxygen saturation of 93% on room air. The chest
was clear with normal heart sounds on auscultation. He
was treated with intravenous ceftriaxone and trimetho-
prim/sulfamethoxazole for presumed community-acquired
pneumonia and possible PCP. The complete blood count
andcomprehensivemetabolicpanelwereunremarkable.The
chest radiograph revealed normal lung ﬁelds. Blood cultures
were negative. A high resolution CT scan of the chest was
performed and was normal. The patient reported subjective
clinical improvement after 48 hours of hospitalization. He
was discharged with a diagnosis of a probable viral upper
respiratory tract infection.
One week later the patient returned to the emergency
department with three days of intermittent fever, cough, and
dyspnea. The CD4 cell count obtained during the previous2 Case Reports in Medicine
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admission returned at 169cells/mm3, with a nondetectable
viral load. His blood pressure was 97/62mm of Hg, temper-
ature 99.9◦F, heart rate 131beats/minute and respiratory rate
of 20breaths/minute, with an oxygen saturation of 96% on
room air and 95% after walking. On physical examination
the patient was dehydrated. The rest of the examination was
unremarkable.
T h ec o m p l e t eb l o o dc o u n t ,c o m p r e h e n s i v em e t a b o l i c
proﬁle, and the chest radiograph were normal. A repeat CT
scan of the chest without contrast revealed a peripherally
located patchy airspace opaciﬁcation on the right side. Blood
cultures showed no growth. Bronchoalveolar lavage was
performed and cultures were negative for bacterial, viral,
mycobacterial, or fungal growth. A Doppler ultrasound of
both lower extremities did not show evidence of DVT.
AC Ts c a no ft h ec h e s tw i t hc o n t r a s t( Figure 1)w a s
performed to evaluate for pulmonary embolism due to
the persistent cough. It revealed ﬁlling defects consistent
with pulmonary embolism in the right main pulmonary
artery [red arrow] and large arterial branches to the right
upper, middle, and lower lobes and smaller emboli in
the distal branches of the left lower lobe as well. The
peripheral opacity in the right lung ﬁeld was a wedge
infarct [blue arrow].
Antibioticswerediscontinuedandthepatientwasstarted
on intravenous heparin and coumadin. The patient is doing
well 6 months after hospitalization.
3. Discussion
The synergistic interplay of multiple risk factors may con-
tribute to the increased risk of developing a thrombo-
embolic phenomenon in patients with chronic HIV infec-
tion. These include coagulation abnormalities, presence of
opportunistic infections, malignancies [5], and severity of
HIV infection.
A number of abnormalities of coagulation have been
described in patients with HIV infection. The most com-
mon is the lupus anticoagulant found in up to 60% of
the patients and may be associated with major thrombo-
embolic phenomena [6]. The increase in procoagulant
factors like tissue factor and elevated concentrations of
microparticlesareimportantcontributingfactors.Micropar-
ticles are relatively small cellular remnants circulating in
plasma originating from platelets and endothelial cells. In
HIV patients, microparticles also originate from CD4+
lymphocytes, as a direct consequence of HIV infec-
tion and possibly as a reﬂection of CD4+ lymphocyte
apoptosis [1]. Other coagulation abnormalities include
reduced levels of antithrombin III, activated protein S
[1, 7], and activated protein C [8], acquired heparin
cofactor II deﬁciency [9] and increased levels of ﬁbrino-
gen, d-dimer, Von-Willibrand factor, plasminogen activator
inhibitor-1, and tissue-type plasminogen activator antigen
[10].
Two epidemiological studies showed higher risk of
venous thromboembolism in patients with CD4 cell count
less than 200cells/mm3. This level of CD4 count predisposes
to many opportunistic infections further contributing to a
procoagulant state through enhancing the active ongoing
immune response. Several opportunistic infections, partic-
ularly Cytomegalovirus and Herpes simplex virus types 1 and
2, may contribute to the prothrombotic state by converting
vascular endothelial cells from a noncoagulative to a proco-
agulative phenotype, leading to expression of procoagulant
phospholipids [8].Anassociation betweencigarettesmoking
and spontaneous thrombosis in HIV patients has been men-
tioned [11]a n dw a sr e p o r t e dt oa ﬀect 77% of the patients
[12].
Pulmonary embolism can masquerade pneumonia. In
patients with a new diagnosis of pulmonary embolism but
with no previous history of thromboembolic or cardiopul-
monary disorders, cough (28%), pleuritic pain (57%), fever
(3%), and abnormal lung examination (26%) [13]m a yb e
present at initial presentation mimicking a pneumonia or
opportunistic pulmonary infection.
The use of protease inhibitors has also been implicated
in hypercoaguability [1, 8, 14]. Majluf-Cruz et al. [8]f o u n d
that the incidence of venous thrombotic events increased
dramatically from 0.19% before the introduction of protease
inhibitors to 1.07% afterwards. An interesting suggestion
by Saif et al. [15] was that because aspartyl proteases such
as renin, endothelin, and cathepsin D are involved in the
regulation of coagulation, and because the HIV protease
is an aspartyl protease, inhibition of these native proteases
by HIV-protease inhibitors may lead to a prothrombotic
state.
The relationship between HIV infection and the devel-
opment of thrombotic events, either arterial or venous,
is dependent on the interplay amongst multiple fac-
tors, which include coagulation abnormalities, status of
immunity, and ARVs. Because, available evidence support-
ing the above relationship is limited, more research is
required in this area. Physicians need to be aware of the
increasedriskofthrombo-embolicdisordersinHIV-infected
patients so that they can be appropriately recognized and
treated.Case Reports in Medicine 3
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